CDKL5 deficiency-related neurodevelopmental disorders: a multi-center cohort study in Italy.
Antiseizure medication
CDKL5 deficiency disorder
Cortical blindness
EEG
Hypermotor-tonic-spasms sequence seizures
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
received:
24
01
2024
accepted:
26
04
2024
revised:
26
04
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
aheadofprint
Résumé
CDKL5 deficiency disorder (CDD) is a complex clinical condition resulting from non-functional or absent CDKL5 protein, a serine-threonine kinase pivotal for neural maturation and synaptogenesis. The disorder manifests primarily as developmental epileptic encephalopathy, with associated neurological phenotypes, such as hypotonia, movement disorders, visual impairment, and gastrointestinal issues. Its prevalence is estimated at 1 in 40,000-60,000 live births, and it is more prevalent in females due to the lethality of germline mutations in males during fetal development. This Italian multi-center observational study focused on 34 patients with CDKL5-related epileptic encephalopathy, aiming to enhance the understanding of the clinical and molecular aspects of CDD. The study, conducted across 14 pediatric neurology tertiary care centers in Italy, covered various aspects, including phenotypic presentations, seizure types, EEG patterns, treatments, neuroimaging findings, severity of psychomotor delay, and variant-phenotype correlations. The results highlighted the heterogeneity of seizure patterns, with hypermotor-tonic-spasms sequence seizures (HTSS) noted in 17.6% of patients. The study revealed a lack of clear genotype-phenotype correlation within the cohort. The presence of HTSS or HTSS-like at onset resulted a negative prognostic factor for the presence of daily seizures at long-term follow-up in CDD patients. Despite extensive polypharmacotherapy, including medications such as valproic acid, clobazam, cannabidiol, and others, sustained seizure freedom proved elusive, affirming the inherent drug-resistant nature of CDD. The findings underscored the need for further research to explore response rates to different treatments and the potential role of non-pharmacological interventions in managing this challenging disorder.
Identifiants
pubmed: 38874638
doi: 10.1007/s00415-024-12421-1
pii: 10.1007/s00415-024-12421-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Olson HE, Demarest ST, Pestana-Knight EM et al (2019) Cyclin-dependent kinase-like 5 deficiency disorder: clinical review. Pediatr Neurol 97:18–25
doi: 10.1016/j.pediatrneurol.2019.02.015
pubmed: 30928302
pmcid: 7120929
Fehr S, Wong K, Chin R et al (2016) Seizure variables and their relationship to genotype and functional abilities in the CDKL5 disorder. Neurology 87:2206–2213
doi: 10.1212/WNL.0000000000003352
pubmed: 27770071
Fehr S, Downs J, Ho G et al (2016) Functional abilities in children and adults with the CDKL5 disorder. Am J Med Genet A 170:2860–2869
doi: 10.1002/ajmg.a.37851
pubmed: 27528505
Hagebeuk EE, Marcelis CL, Alders M, Kaspers A, deWeerd AW (2015) Two siblings with a CDKL5 mutation: genotype and phenotype evaluation. J Child Neurol 30:1515–1519
doi: 10.1177/0883073815573317
pubmed: 25762588
Mangatt M, Wong K, Anderson B, Epstein A, Hodgetts S, Leonard H, Downs J (2016) Prevalence and onset of comorbidities in the CDKL5 disorder differ from Rett syndrome. Orphanet J Rare Dis 11:39
doi: 10.1186/s13023-016-0418-y
pubmed: 27080038
pmcid: 4832563
Bahi-Buisson N, Bienvenu T (2012) CDKL5-related disorders: from clinical description to molecular genetics. Mol Syndromol 2:137–152
doi: 10.1159/000331333
pubmed: 22670135
Liang J-S, Huang H, Wang J-S, Lu J-F (2019) Phenotypic manifestations between male and female children with CDKL5 mutations. Brain Dev 41:783–789
doi: 10.1016/j.braindev.2019.05.003
pubmed: 31122804
Fisher RS, Cross JH, French JA et al (2017) Operational classification of seizure types by the international league against epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia 58:522–530
doi: 10.1111/epi.13670
pubmed: 28276060
Klein KM, Yendle SC, Harvey AS et al (2011) A distinctive seizure type in patients with CDKL5 mutations: hypermotor-tonic-spasms sequence. Neurology 76:1436–1438
doi: 10.1212/WNL.0b013e3182166e58
pubmed: 21502606
Demarest ST, Olson HE, Moss A et al (2019) CDKL5 deficiency disorder: relationship between genotype, epilepsy, cortical visual impairment, and development. Epilepsia 60:1733–1742
doi: 10.1111/epi.16285
pubmed: 31313283
pmcid: 7098045
Fehr S, Leonard H, Ho G et al (2015) There is variability in the attainment of developmental milestones in the CDKL5 disorder. J Neurodev Disord. https://doi.org/10.1186/1866-1955-7-2
doi: 10.1186/1866-1955-7-2
pubmed: 25657822
pmcid: 4318547
MacKay CI, Bick D, Prokop JW, Muñoz I, Rouse J, Downs J, Leonard H (2020) Expanding the phenotype of the CDKL5 deficiency disorder: are seizures mandatory? Am J Med Genet A 182:1217–1222
doi: 10.1002/ajmg.a.61504
pubmed: 32034940
Leonard H, Downs J, Benke TA, Swanson L, Olson H, Demarest S (2022) CDKL5 deficiency disorder: clinical features, diagnosis, and management. Lancet Neurol 21:563–576
doi: 10.1016/S1474-4422(22)00035-7
pubmed: 35483386
pmcid: 9788833
Fehr S, Wilson M, Downs J, Williams S, Murgia A, Sartori S et al (2013) The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur J Hum Genet 21:266–273
doi: 10.1038/ejhg.2012.156
pubmed: 22872100
Müller A, Helbig I, Jansen C, Bast T, Guerrini R, Jähn J et al (2016) Retrospective evaluation of low long-term efficacy of antiepileptic drugs and ketogenic diet in 39 patients with CDKL5-related epilepsy. Eur J Paediatr Neurol 20:147–151
doi: 10.1016/j.ejpn.2015.09.001
pubmed: 26387070
Demarest ST, Shellhaas RA, Gaillard WD, Keator C, Nickels KC, Hussain SA, Pediatric Epilepsy Research Consortium et al (2017) The impact of hypsarrhythmia on infantile spasms treatment response: observational cohort study from the National Infantile Spasms Consortium. Epilepsia 58:2098–2103
doi: 10.1111/epi.13937
pubmed: 29105055
pmcid: 5863227
Olson HE, Demarest S, Pestana-Knight E, Moosa AN, Zhang X, Pérez-Pérez JR et al (2023) Epileptic spasms in CDKL5 deficiency disorder: Delayed treatment and poor response to first-line therapies. Epilepsia 64:1821–1832
doi: 10.1111/epi.17630
pubmed: 37114835
Bahi-Buisson N, Nectoux J, Rosas-Vargas H, Milh M, Boddaert N, Girard B et al (2008) Key clinical features to identify girls with CDKL5 mutations. Brain 131:2647–2661
doi: 10.1093/brain/awn197
pubmed: 18790821
Tascini G, Dell’Isola GB, Mencaroni E, Di Cara G, Striano P, Verrotti A (2022) Sleep disorders in Rett syndrome and Rett-related disorders: a narrative review. Front Neurol 13:817195
doi: 10.3389/fneur.2022.817195
pubmed: 35299616
pmcid: 8923297
Dell’Isola GB, Portwood KE, Consing K, Fattorusso A, Bartocci A, Ferrara P et al (2024) Current overview of CDKL-5 deficiency disorder treatment. Pediatr Rep 16:21–25. https://doi.org/10.3390/pediatric16010002
doi: 10.3390/pediatric16010002
pubmed: 38251311
pmcid: 10801578
Olson HE, Daniels CI, Haviland I et al (2021) Current neurologic treatment and emerging therapies in CDKL5 deficiency disorder. J Neurodev Disord 13:40
doi: 10.1186/s11689-021-09384-z
pubmed: 34530725
pmcid: 8447578